Leerink Partners Maintains Exact Sciences(EXAS.US) With Buy Rating
Buy Rating for Exact Sciences as Cologuard Plus Poised for Growth and Upside Pricing Potential
TD Cowen Maintains Exact Sciences(EXAS.US) With Buy Rating, Maintains Target Price $80
Analysts Are Bullish on These Healthcare Stocks: Exact Sciences (EXAS), AdaptHealth (AHCO)
Exact Sciences, Quanterix Extend Slide After Medicare Rates
Wolfe Research Maintains Exact Sciences(EXAS.US) With Buy Rating, Cuts Target Price to $75
Optimistic Outlook on Exact Sciences's Stock Despite CLFS Rate Stasis
Raymond James Reiterates Market Perform on Exact Sciences
Exact Sciences Analyst Ratings
Hyper Personalized Medicine Research Report 2024: A $5.5 Trillion Market in 2023 - Global Forecast to 2030 Featuring QIAGEN, Danaher, Illumina, GE, Exagen, Abbott, Exact Sciences, Dako, Decode
BTIG Maintains Exact Sciences(EXAS.US) With Buy Rating, Maintains Target Price $82
BTIG Sticks to Their Buy Rating for Exact Sciences (EXAS)
S&P 500 Futures Up In Premarket Trading; Simpson Manufacturing, Intel Lead
Exact Sciences EVP Sells Shares Worth Over $65,000
10 Health Care Stocks With Whale Alerts In Today's Session
28 Top Rated U.S. Growth Stocks Month-to-date in Anticipation of Fed Cuts
Jefferies Maintains Exact Sciences(EXAS.US) With Buy Rating, Maintains Target Price $84
Jefferies analyst Tycho Peterson maintains $Exact Sciences(EXAS.US)$ with a buy rating, and maintains the target price at $84.According to TipRanks data, the analyst has a success rate of 58.4% and
A Quick Look at Today's Ratings for Exact Sciences(EXAS.US), With a Forecast Between $75 to $84
On Sep 17, major Wall Street analysts update their ratings for $Exact Sciences(EXAS.US)$, with price targets ranging from $75 to $84.Citi analyst Patrick B Donnelly maintains with a buy rating, and
The Battle Brewing Over Blood Tests for Cancer -- Heard on the Street -- WSJ
Express News | Exact Sciences Corp : Btig Raises Target Price to $82 From $70